Cited 25 times in
Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최동훈 | - |
dc.date.accessioned | 2017-10-26T07:21:25Z | - |
dc.date.available | 2017-10-26T07:21:25Z | - |
dc.date.issued | 2016 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/151921 | - |
dc.description.abstract | The pill burden of patients with hypertension and dyslipidemia can result in poor medication compliance. This study aimed to evaluate the efficacy and safety of fixed-dose combination (FDC) therapy with olmesartan medoxomil (40 mg) and rosuvastatin (20 mg) in Korean patients with mild to moderate hypertension and dyslipidemia. This multicenter, randomized, double-blind, factorial-design study included patients aged ≥20 years with mild to moderate essential hypertension and dyslipidemia. Patients were randomly assigned to receive FDC therapy (40 mg olmesartan medoxomil, 20 mg rosuvastatin), 40 mg olmesartan medoxomil, 20 mg rosuvastatin, or a placebo. The percentage change from baseline in low-density lipoprotein cholesterol levels was compared between FDC therapy and olmesartan medoxomil, and the change from baseline in diastolic blood pressure was compared between FDC therapy and rosuvastatin 8 weeks after treatment. A total of 162 patients were included. The least square mean percentage change (standard error) from baseline in low-density lipoprotein cholesterol levels 8 weeks after treatment was significantly greater in the FDC than in the olmesartan medoxomil group (-52.3% [2.8%] vs -0.6% [3.5%], P<0.0001), and the difference was -51.7% (4.1%) (95% confidence interval: -59.8% to -43.6%). The least square mean change (standard error) from baseline in diastolic blood pressure 8 weeks after treatment was significantly greater in the FDC group than in the rosuvastatin group (-10.4 [1.2] mmHg vs 0.1 [1.6] mmHg, P<0.0001), and the difference was -10.5 (1.8) mmHg (95% confidence interval: -14.1 to -6.9 mmHg). There were 50 adverse events in 41 patients (22.7%) and eight adverse drug reactions in five patients (2.8%). The study found that FDC therapy with olmesartan medoxomil and rosuvastatin is an effective, safe treatment for patients with hypertension and dyslipidemia. This combination may improve medication compliance in patients with a large pill burden. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Dove Press Limited | - |
dc.relation.isPartOf | DRUG DESIGN DEVELOPMENT AND THERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Antihypertensive Agents/administration & dosage | - |
dc.subject.MESH | Antihypertensive Agents/adverse effects | - |
dc.subject.MESH | Antihypertensive Agents/therapeutic use* | - |
dc.subject.MESH | Double-Blind Method | - |
dc.subject.MESH | Drug Combinations | - |
dc.subject.MESH | Dyslipidemias/drug therapy* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hypertension/drug therapy* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Olmesartan Medoxomil/administration & dosage | - |
dc.subject.MESH | Olmesartan Medoxomil/adverse effects | - |
dc.subject.MESH | Olmesartan Medoxomil/therapeutic use* | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Rosuvastatin Calcium/administration & dosage | - |
dc.subject.MESH | Rosuvastatin Calcium/adverse effects | - |
dc.subject.MESH | Rosuvastatin Calcium/therapeutic use* | - |
dc.title | Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong) | - |
dc.type | Article | - |
dc.publisher.location | New Zealand | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Jin-Sun Park | - |
dc.contributor.googleauthor | Joon-Han Shin | - |
dc.contributor.googleauthor | Taek-Jong Hong | - |
dc.contributor.googleauthor | Hong-Seog Seo | - |
dc.contributor.googleauthor | Wan-Joo Shim | - |
dc.contributor.googleauthor | Sang-Hong Baek | - |
dc.contributor.googleauthor | Jin-Ok Jeong | - |
dc.contributor.googleauthor | Youngkeun Ahn | - |
dc.contributor.googleauthor | Woong-Chol Kang | - |
dc.contributor.googleauthor | Young-Hak Kim | - |
dc.contributor.googleauthor | Sang-Hyun Kim | - |
dc.contributor.googleauthor | Min-Su Hyon | - |
dc.contributor.googleauthor | Dong-Hoon Choi | - |
dc.contributor.googleauthor | Chang-Wook Nam | - |
dc.contributor.googleauthor | Tae-Ho Park | - |
dc.contributor.googleauthor | Sang-Chol Lee | - |
dc.contributor.googleauthor | Hyo-Soo Kim | - |
dc.identifier.doi | 10.2147/DDDT.S112873 | - |
dc.contributor.localId | A04053 | - |
dc.relation.journalcode | J02859 | - |
dc.identifier.eissn | 1177-8881 | - |
dc.identifier.pmid | 27574399 | - |
dc.subject.keyword | dyslipidemia | - |
dc.subject.keyword | fixed-dose combination therapy | - |
dc.subject.keyword | hypertension | - |
dc.subject.keyword | olmesartan medoxomil | - |
dc.subject.keyword | rosuvastatin | - |
dc.contributor.alternativeName | Choi, Dong Hoon | - |
dc.contributor.affiliatedAuthor | Choi, Dong Hoon | - |
dc.citation.volume | 10 | - |
dc.citation.startPage | 2599 | - |
dc.citation.endPage | 2609 | - |
dc.identifier.bibliographicCitation | DRUG DESIGN DEVELOPMENT AND THERAPY, Vol.10 : 2599-2609, 2016 | - |
dc.date.modified | 2017-10-24 | - |
dc.identifier.rimsid | 46246 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.